156 related articles for article (PubMed ID: 21330337)
1. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Salama JK; Haraf DJ; Stenson KM; Blair EA; Witt ME; Williams R; Kunnavakkam R; Cohen EE; Seiwert T; Vokes EE
Ann Oncol; 2011 Oct; 22(10):2304-9. PubMed ID: 21330337
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Seiwert TY; Haraf DJ; Cohen EE; Stenson K; Witt ME; Dekker A; Kocherginsky M; Weichselbaum RR; Chen HX; Vokes EE
J Clin Oncol; 2008 Apr; 26(10):1732-41. PubMed ID: 18375903
[TBL] [Abstract][Full Text] [Related]
4. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Cohen EE; Haraf DJ; List MA; Kocherginsky M; Mittal BB; Rosen F; Brockstein B; Williams R; Witt ME; Stenson KM; Kies MS; Vokes EE
J Clin Oncol; 2006 Jul; 24(21):3438-44. PubMed ID: 16849759
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Haraf DJ; Kies M; Rademaker AW; Stenson K; Mittal B; Pelzer H; Wenig B; Witt ME; Sulzen L; Weichselbaum RR; Vokes EE
J Clin Oncol; 1999 Feb; 17(2):638-44. PubMed ID: 10080609
[TBL] [Abstract][Full Text] [Related]
6. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
7. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Vokes EE; Weichselbaum RR; Mick R; McEvilly JM; Haraf DJ; Panje WR
J Natl Cancer Inst; 1992 Jun; 84(11):877-82. PubMed ID: 1375657
[TBL] [Abstract][Full Text] [Related]
8. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
[TBL] [Abstract][Full Text] [Related]
9. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Argiris A; Haraf DJ; Kies MS; Vokes EE
Oncologist; 2003; 8(4):350-60. PubMed ID: 12897332
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Vokes EE; Panje WR; Schilsky RL; Mick R; Awan AM; Moran WJ; Goldman MD; Tybor AG; Weichselbaum RR
J Clin Oncol; 1989 Jun; 7(6):761-8. PubMed ID: 2715806
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Salama JK; Vokes EE; Chmura SJ; Milano MT; Kao J; Stenson KM; Witt ME; Haraf DJ
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):382-91. PubMed ID: 16213104
[TBL] [Abstract][Full Text] [Related]
15. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Merlano M; Benasso M; Corvò R; Rosso R; Vitale V; Blengio F; Numico G; Margarino G; Bonelli L; Santi L
J Natl Cancer Inst; 1996 May; 88(9):583-9. PubMed ID: 8609658
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E
J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Salama JK; Stenson KM; Kistner EO; Mittal BB; Argiris A; Witt ME; Rosen F; Brockstein BE; Cohen EE; Haraf DJ; Vokes EE
Ann Oncol; 2008 Oct; 19(10):1787-94. PubMed ID: 18539617
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Vokes EE; Haraf DJ; McEvilly JM; Mick R; Kozloff MF; Goldman MD; Moran WJ; Clendeninn NJ; Collier MA; Weichselbaum RR
Ann Oncol; 1992 Jan; 3(1):79-81. PubMed ID: 1606074
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Fountzilas G; Nicolaou A; Sridhar K; Sideras T; Haritanti A; Anastasakis C; Delis V; Vritsios A; Daniilidis J
Arch Otorhinolaryngol; 1989; 246(5):373-7. PubMed ID: 2480104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
